

PFIZER (PFE)

Pharmaceutical and consumer products company, which discovers, develops, manufactures and markets innovative medicines for humans and animals.

Drugs

Current Data

Current Price	\$32.38
Market Cap (mil)	\$247,076
Common Shares out (mil)	7,630.5
Shrs Held by Insitutions	63%
Average Daily Volume (100s)	154,544
Beta (Adjusted)	0.63
Exchange	NYSE
Options Trading	Yes
Latest Qtr Report	03/2004


12 Mo Sales (mil)	\$49,151
12 Mo EPS	\$0.19
12 Mo Operating EPS	\$1.62
FirstCall EPS Est FY1	\$2.11
FirstCall EPS Est FY2	\$2.36
Cash Flow/Share (FY)	\$0.75
Annual Dividend	\$0.68
Dividend Payout Ratio	42.0%
Dividend Yield	2.1%

Ford Evaluations

Quality Rating	A
Growth Persistence Rating	A
Projected Growth Rate	15.0%
Ford DDM Value	\$68.78
Share Buyback (12-Mo % Chg)	-3.3%
Normal Earnings	\$1.70
Price/Normal Earnings	19.0
Price/Operating Earnings	20.0
Price/Ford Value (PVA)	0.47

Price Performance

SAMPLE



Earnings Data

Fiscal Year End	December 1999	December 2000	December 2001	December 2002	December 2003
Sales (mil)	\$16,204	\$29,574	\$32,259	\$32,373	\$45,188
EPS	\$0.87	\$1.05	\$1.31	\$1.60	\$1.75
Net Profit on Sales (%)	20.7	22.4	25.5	30.5	29.5
Cash Flow/Share	\$0.97	\$0.74	\$1.41	\$1.66	\$0.75
Book Value/Share	\$2.25	\$2.50	\$2.88	\$3.25	\$8.63
Return on Equity (%)	38.7	42.0	45.6	49.2	20.3
Debt to Equity (%)	6.0	10.0	14.0	16.0	9.0

<p>Valuation Ratios</p> <table border="1"> <thead> <tr> <th></th> <th>5 Year Low</th> <th>5 Year High</th> </tr> </thead> <tbody> <tr><td>Price/Earnings</td><td>18.4</td><td>51.7</td></tr> <tr><td>Price/Cash Flow</td><td>18.0</td><td>63.0</td></tr> <tr><td>Price/Book Value</td><td>3.51</td><td>17.92</td></tr> <tr><td>Price/Sales</td><td>5.47</td><td>17.92</td></tr> <tr><td>Price/Value</td><td>0.36</td><td>1.95</td></tr> </tbody> </table>		5 Year Low	5 Year High	Price/Earnings	18.4	51.7	Price/Cash Flow	18.0	63.0	Price/Book Value	3.51	17.92	Price/Sales	5.47	17.92	Price/Value	0.36	1.95	<p>Sales Growth</p> <table border="1"> <thead> <tr> <th></th> <th>PFE</th> <th>Industry Avg</th> </tr> </thead> <tbody> <tr><td>5 Year</td><td>21.8</td><td>11.1</td></tr> <tr><td>12 Month</td><td>48.4</td><td>15.4</td></tr> <tr><td>Last Qtr</td><td>46.8</td><td>11.6</td></tr> </tbody> </table>		PFE	Industry Avg	5 Year	21.8	11.1	12 Month	48.4	15.4	Last Qtr	46.8	11.6	<p>Earnings Growth</p> <table border="1"> <thead> <tr> <th></th> <th>PFE</th> <th>Industry Avg</th> </tr> </thead> <tbody> <tr><td>5 Year</td><td>18.6</td><td>9.6</td></tr> <tr><td>12 Month</td><td>-2.4</td><td>15.4</td></tr> <tr><td>Last Qtr</td><td>-29</td><td>28.0</td></tr> <tr><td>1 Yr Est</td><td>21.1</td><td>26.8</td></tr> <tr><td>2 Yr Est</td><td>11.8</td><td>8.0</td></tr> </tbody> </table>		PFE	Industry Avg	5 Year	18.6	9.6	12 Month	-2.4	15.4	Last Qtr	-29	28.0	1 Yr Est	21.1	26.8	2 Yr Est	11.8	8.0	
	5 Year Low	5 Year High																																																	
Price/Earnings	18.4	51.7																																																	
Price/Cash Flow	18.0	63.0																																																	
Price/Book Value	3.51	17.92																																																	
Price/Sales	5.47	17.92																																																	
Price/Value	0.36	1.95																																																	
	PFE	Industry Avg																																																	
5 Year	21.8	11.1																																																	
12 Month	48.4	15.4																																																	
Last Qtr	46.8	11.6																																																	
	PFE	Industry Avg																																																	
5 Year	18.6	9.6																																																	
12 Month	-2.4	15.4																																																	
Last Qtr	-29	28.0																																																	
1 Yr Est	21.1	26.8																																																	
2 Yr Est	11.8	8.0																																																	
<p>Industry Group</p> <table border="1"> <thead> <tr> <th></th> <th>Price</th> <th>P/E</th> </tr> </thead> <tbody> <tr><td>PFIZER (PFE)</td><td>\$32.38</td><td>20.0</td></tr> <tr><td>ABBOTT LABS (ABT)</td><td>\$39.10</td><td>17.1</td></tr> <tr><td>AVENTIS (AVE)</td><td>\$79.17</td><td>21.7</td></tr> <tr><td>BRISTOL-MYERS SQ (BMY)</td><td>\$23.56</td><td>14.0</td></tr> <tr><td>GLAXOSMITHKLINE (GSK)</td><td>\$39.39</td><td>14.9</td></tr> <tr><td>MERCK (MRK)</td><td>\$44.80</td><td>14.7</td></tr> <tr><td>NOVARTIS AG (NVS)</td><td>\$43.50</td><td>20.7</td></tr> <tr><td>WYETH (WYE)</td><td>\$34.32</td><td>13.6</td></tr> </tbody> </table>		Price	P/E	PFIZER (PFE)	\$32.38	20.0	ABBOTT LABS (ABT)	\$39.10	17.1	AVENTIS (AVE)	\$79.17	21.7	BRISTOL-MYERS SQ (BMY)	\$23.56	14.0	GLAXOSMITHKLINE (GSK)	\$39.39	14.9	MERCK (MRK)	\$44.80	14.7	NOVARTIS AG (NVS)	\$43.50	20.7	WYETH (WYE)	\$34.32	13.6	<p>Ford Model Percentiles</p> <p>Percentile Scores of Ford Universe (100=best, 1=worst)</p> <table border="1"> <thead> <tr> <th>Momentum</th> <th>Score</th> </tr> </thead> <tbody> <tr><td>Value</td><td>84</td></tr> <tr><td>EPS</td><td>50</td></tr> <tr><td>Sales</td><td>53</td></tr> <tr><td>Price</td><td>57</td></tr> </tbody> </table>	Momentum	Score	Value	84	EPS	50	Sales	53	Price	57	<p>Earnings Trend</p> <p>Trailing Operating 12 Month EPS in US \$</p> <table border="1"> <thead> <tr> <th>Period</th> <th>EPS</th> </tr> </thead> <tbody> <tr><td>6/03</td><td>1.60</td></tr> <tr><td>9/03</td><td>1.60</td></tr> <tr><td>12/03</td><td>1.60</td></tr> <tr><td>3/04</td><td>1.60</td></tr> <tr><td>6/04e</td><td>1.60</td></tr> </tbody> </table>	Period	EPS	6/03	1.60	9/03	1.60	12/03	1.60	3/04	1.60	6/04e	1.60
	Price	P/E																																																	
PFIZER (PFE)	\$32.38	20.0																																																	
ABBOTT LABS (ABT)	\$39.10	17.1																																																	
AVENTIS (AVE)	\$79.17	21.7																																																	
BRISTOL-MYERS SQ (BMY)	\$23.56	14.0																																																	
GLAXOSMITHKLINE (GSK)	\$39.39	14.9																																																	
MERCK (MRK)	\$44.80	14.7																																																	
NOVARTIS AG (NVS)	\$43.50	20.7																																																	
WYETH (WYE)	\$34.32	13.6																																																	
Momentum	Score																																																		
Value	84																																																		
EPS	50																																																		
Sales	53																																																		
Price	57																																																		
Period	EPS																																																		
6/03	1.60																																																		
9/03	1.60																																																		
12/03	1.60																																																		
3/04	1.60																																																		
6/04e	1.60																																																		